Liver Transplant Rejection
📧 Sign up to get email alerts when something new happens for Liver Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited under ANDA 212087.
-
FDA approval · 2024-08-09FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Accord Healthcare Inc.'s mycophenolate mofetil under an ANDA. The approval updates the generic p…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension [Phase 2]
A Phase 2 study of CFZ533, an anti-CD40 monoclonal antibody, in liver transplant recipients was terminated, with results including 12-month …
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: Safety of DNP007 in Healthy Subjects [Phase 1]
Phase 1 trial evaluating the safety of DNP007 in healthy subjects, with listed conditions including liver transplant rejection, complication…
-
FDA approval · 2024-05-21FDA Approved: CYCLOSPORINE — Original Application (Devatis Inc.)
FDA approved Devatis Inc.'s cyclosporine as a generic drug under an original ANDA (ANDA209811).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients [Phase 4]
Phase 4 clinical trial assessing erythropoietin therapy to induce regulatory T cells in liver transplant recipients with rejection.
-
FDA approval · 2024-02-20FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for a generic version of mycophenolate mofetil (Aurobindo Pharma Limited) to prevent organ transplant …
-
FDA approval · 2024-01-25FDA Approved: TACROLIMUS — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved TACROLIMUS under Original Application from Amneal Pharmaceuticals NY LLC, including standard and extended-release capsule formu…
-
FDA approval · 2024-01-05FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for mycophenolate mofetil from Aurobindo Pharma Limited, authorizing the generic immunosuppressant for…
-
FDA approval · 2024-01-03FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' supplemental application for mycophenolate mofetil (ANDA 091249).
-
FDA approval · 2023-11-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Biocon Pharma Inc.)
FDA approved mycophenolic acid from Biocon Pharma Inc. via an original application. It is indicated to prevent organ transplant rejection in…
-
FDA approval · 2023-09-14FDA Approved: ASTAGRAF XL — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for ASTAGRAF XL (tacrolimus extended-release capsules) from Astellas Pharma US, Inc.
-
FDA approval · 2023-06-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for mycophenolate mofetil filed by Meitheal Pharmaceuticals Inc. The approval relates to an addition…
-
FDA approval · 2023-06-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (ONESOURCE SPECIALTY PHARMA LIMITED)
FDA approved a supplemental application for mycophenolate mofetil submitted by Onesource Specialty Pharma Limited.
-
FDA approval · 2023-04-19FDA Approved: TACROLIMUS — Supplemental Application (Ascend Laboratories, LLC)
The FDA has approved a supplemental application for tacrolimus from Ascend Laboratories, LLC.
-
FDA approval · 2022-12-23FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (ONESOURCE SPECIALTY PHARMA LIMITED)
FDA approved an original application for mycophenolate mofetil, a generic immunosuppressant used to prevent organ transplant rejection.
-
FDA approval · 2022-11-16FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited.
-
FDA approval · 2022-08-10FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil) filed by Genentech, updating the labeling to reflect the approv…
-
FDA approval · 2022-08-10FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil hydrochloride) submitted by Genentech, Inc.
-
CLINICAL_TRIALS research · 2022-07-14Clinical Trial Update: SRL (Sirolimus) Withdrawal [NA]
A completed clinical trial update on sirolimus withdrawal in the context of liver transplant acute rejection and immunosuppressant therapy e…
-
FDA approval · 2022-03-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for mycophenolate mofetil (generic) submitted by Mylan Pharmaceuticals, granting approval under an A…
-
FDA approval · 2021-11-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Biocon Pharma Inc.)
FDA approved an original application for mycophenolic acid (Biocon Pharma Inc.), establishing a generic version of the immunosuppressant.
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved Genentech's supplemental application for CELLCEPT (mycophenolate mofetil).
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approves a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) submitted by Genentech, Inc.